Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

| More on:
A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes.

Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:

Coles Group Ltd (ASX: COL)

According to a note out of Citi, analysts have retained their buy rating and $19.00 price target on this supermarket giant's shares. Citi has been visiting stores to get a better idea of how the big two supermarket operators are performing with their respective strategies. It believes that Coles' pricing strategy is resonating more with consumers and will result in stronger sales growth during the fourth quarter of FY 2024. This is based on its belief that Coles' strategy is being executed better and has a stronger value perception. And while Citi rates both supermarket giants as buys, its preference at this point is Coles. The Coles share price ended the week at $16.42.

Pro Medicus Limited (ASX: PME)

A note out of Goldman Sachs reveals that its analysts have reiterated their buy rating on this health imaging technology company's shares with an improved price target of $136.00. This follows news that Pro Medicus has won five new contracts with a minimum contract value of $45 million. Goldman highlights that this brings the company's minimum total contract value (TCV) for new sales this financial year to $245 million. And there's still potential for more contract wins given its sizeable sales pipeline. Goldman believes this supports its view that the company's Visage 7 software is an industry-leading solution and that the company is the incumbent technology leader in radiology and well-placed to take market share. The Pro Medicus share price was fetching $120.12 at Friday's close.

Qantas Airways Limited (ASX: QAN)

Another note out of Goldman Sachs reveals that its analysts have retained their buy rating and $8.05 price target on this airline operator's shares. Goldman believes that the market is severely undervaluing Qantas' shares. It suspects that this could be due to investors pricing in a trade off between investment (fleet and customer) and capital returns (dividends and buybacks). However, the broker believes that Qantas can return significant capital to shareholders and invest in its fleet while still maintaining a strong balance sheet. As a result, its analysts see the Flying Kangaroo's cheap valuation as a buying opportunity. It is also worth noting that Goldman is expecting the Qantas dividend to return in 2025. The Qantas share price ended the week at $6.15.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Pro Medicus. The Motley Fool Australia has positions in and has recommended Coles Group. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Broker written in white with a man drawing a yellow underline.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Broker Notes

This speculative ASX stock could almost double in value

Bell Potter thinks investors could almost double their money with this high risk option.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

This ASX 200 stock's 'compelling valuation' makes it a strong buy

Goldman Sachs thinks a 50% return could be on the cards for investors.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX shares could rise 25% to ~50%

Big returns could await buyers of these shares according to analysts.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

rising asx share price represented by man with arms raised against blackboard featuring images of dollar notes
Broker Notes

Why these 3 ASX 200 shares just earned substantial broker upgrades

Top brokers just increased their share price forecasts for these three ASX 200 shares. But why?

Read more »

Two smiling men in high visibility vests and yellow hardhats stand side by side with a large mound of earth and mining equipment behind them smiling as the Carnaby Resources share price rises today
Broker Notes

See why this broker just upgraded South32 shares to a buy

Commodity prices continue to create tailwinds for ASX stocks.

Read more »